EQUITY RESEARCH MEMO

2KMM

Generated 5/3/2026

Executive Summary

Conviction (model self-assessment)55/100

2KMM is a Polish contract research organization (CRO) and IT services company that bridges life sciences and information technology. Founded in 2012, the company offers comprehensive support for clinical trials, observational studies, and patient registries, leveraging its proprietary electronic data capture (EDC) and clinical trial management software (CTMS). By integrating traditional CRO services such as data management and biostatistics with specialized IT development, testing, and validation, 2KMM provides a unique value proposition to pharmaceutical and biotech clients. The company operates out of Warsaw, Poland, and is privately held. While its financial details and stage are undisclosed, its dual focus on CRO and software services positions it well in the growing clinical trial outsourcing market, particularly in Central and Eastern Europe.

Upcoming Catalysts (preview)

  • TBDMajor Contract Win with a Top Pharma or Biotech30% success
  • TBDRelease of Next-Generation EDC/CTMS Platform40% success
  • TBDExpansion into New Therapeutic Areas or Geographic Markets35% success
Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)